CEO Ramji cites elongated sales cycles and lower pricing gains from product migrations.

Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, […]

Cellebrite DI (CLBT) has come under fresh scrutiny after its August 13 Q2 2026 earnings report, guidance cut, and CEO transition, with Levi & Korsinsky launching an investigation following a sharp post results share price decline. See our latest analysis for Cellebrite DI. Cellebrite DI’s latest earnings miss, guidance reset and CEO change have coincided with sharp selling, with the share price down 29.18% over one day and 33.25% over 30 days, while the 3 year total shareholder return remains...

In August 2026, Cellebrite DI Ltd. reported second-quarter results showing revenue of US$131.14 million and net income of US$6.37 million, while lowering its full-year 2026 revenue guidance to US$555 million–US$561 million and announcing Shiven Ramji’s appointment as CEO, succeeding Thomas E. Hogan. The combination of reduced revenue expectations, softer profitability, and a leadership transition raises questions about how quickly Cellebrite can convert its product and AI investments,...

Cellebrite DI (NasdaqGS: CLBT) announced a planned CEO transition, with Shiven Ramji set to succeed Thomas E. Hogan. Ramji joined Cellebrite DI earlier this year as President, Products and Technology and was recently appointed to the board. The company described the move as part of a succession plan, indicating possible changes in leadership focus and execution priorities. This kind of leadership change is not unique to Cellebrite DI, so it can be useful to compare it with a wider group of...

Guidance cuts, AI spending, leadership changes, EV competition and share dilution rattled investors.

Moby summary of Cellebrite DI Ltd.'s Q2 2026 earnings call

Despite a 21% ARR surge to $508 million, Cellebrite lowers its 2026 revenue forecast due to elongated sales cycles, while raising EBITDA targets on disciplined cost management.

On Aug. 13, 2026, the digital forensics firm reported delays in large transactions and heightened demand for cloud and AI procurement, prompting a leadership change.

Cellebrite DI (NASDAQ:CLBT) reported second-quarter results that fell short of its expectations for annual recurring revenue, citing delayed large transactions, slower-than-anticipated pricing and expansion gains from customer migrations, and added procurement requirements for cloud and artificial i